Neuropathic Ocular Pain Market Size (7MM) is Expected to Grow at a Significant CAGR During the Forecast Period of 2026-2036 | DelveInsight

DelveInsight's "Neuropathic Ocular Pain (NOP) Market Insights, Epidemiology and Market Forecast - 2036" report delivers an in-depth understanding of the NOP, historical and forecasted epidemiology, as well as the NOP market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Neuropathic Ocular Pain Market Report @ https://www.delveinsight.com/report-store/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from Neuropathic Ocular Pain Market Report
• In March 2026, OKYO Pharma Limited reported positive Phase IIa exploratory results for urcosimod (0.05%) in Neuropathic Corneal Pain (NCP), showing clinically meaningful pain reduction, improved quality of life, and potential corneal nerve restoration signals versus placebo after 12 weeks of treatment, with findings to be presented at the 2026 ARVO Annual Meeting.
• In January 2026, OKYO Pharma announced FDA authorization of a compassionate-use IND application for urcosimod (0.05%) to treat a patient with severe NCP who had limited treatment options and no approved therapies available.
• The NOP market in the 7MM was valued at approximately USD XX million in 2025 and is projected to reach USD XX million in 2036, growing at a CAGR of XX% over the forecast period (2026-2036).
• In 2025, the United States accounted for the highest number of NOP cases among the 7MM, and this number is expected to increase throughout the study period.
• The proportion of females affected by NOP is higher than that of males, with women also tending to experience a greater incidence of associated conditions such as fibromyalgia and autoimmune diseases.
• Autoimmune diseases affect approximately 5-8% of the population, with nearly 78% of affected individuals being women, which may contribute to the higher incidence observed in females.
• Currently, there are no FDA approved therapies specifically for NOP, and the pipeline remains limited.
• The Neuropathic Ocular Pain Companies include OKYO Pharma, and others.
• Promising Neuropathic Ocular Pain Therapies include Urcosimod (0.05%; OK-101), and others.

Get a Free sample for the Neuropathic Ocular Pain Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What is Neuropathic Ocular Pain?
NOP is a chronic ocular pain condition caused by damage or dysfunction of the corneal nerves and somatosensory pathways, often occurring in the absence of significant visible ocular surface abnormalities. The condition is characterized by symptoms such as burning, stinging, dryness, photophobia, foreign body sensation, and severe eye discomfort, frequently associated with dry eye disease, refractive surgery, infections, trauma, autoimmune disorders, or systemic neuropathic conditions. NOP can significantly impair quality of life and is often difficult to diagnose and manage due to the overlap of symptoms with other ocular surface disorders and the complex underlying neuro-inflammatory mechanisms. NOP is diagnosed through clinical evaluation, patient history, and exclusion of other ocular surface disorders, with a diagnostic workup that includes ocular surface examination, corneal sensitivity assessment, tear film evaluation, fluorescein staining, and specialized tests such as confocal microscopy or topical anesthetic challenge.

Neuropathic Ocular Pain Epidemiology Segmentation in the 7MM
• Total Cases of Several Eye Disorders and Surgeries
• Total Cases of Neuropathic Ocular Pain (NOP) in Several Eye Disorders and Surgeries
• Total Treated Cases of Neuropathic Ocular Pain (NOP)

Download the report to understand which factors are driving Neuropathic Ocular Pain epidemiology trends @ https://www.delveinsight.com/report-store/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Neuropathic Ocular Pain Approved Therapies
NOP remains a significant unmet need due to the absence of approved disease-specific therapies and the limited effectiveness of current symptomatic treatments, creating substantial opportunities for novel therapeutic development and future research advancements. Currently, there are no FDA approved therapies specifically for NOP. Treatment primarily involves symptomatic and supportive approaches such as lubricating eye drops, topical anti-inflammatory agents, autologous serum tears, corticosteroids, and systemic neuropathic pain medications, including gabapentin and pregabalin for refractory pain, to reduce ocular discomfort, inflammation, and nerve sensitization, although treatment responses remain variable and limited in many patients.

Neuropathic Ocular Pain Pipeline Analysis
• Urcosimod (0.05%; OK-101): OKYO Pharma
Urcosimod (0.05%) is a lipid-conjugated chemerin peptide agonist targeting the ChemR23 receptor on ocular immune and nerve-related cells, developed for dry eye disease and neuropathic corneal pain. It has demonstrated anti-inflammatory and pain-reducing effects in preclinical models and showed significant efficacy in Phase II clinical trials for both neuropathic corneal pain and dry eye disease. The drug has received the first FDA IND and Fast Track designation for the treatment of Neuropathic Corneal Pain (NCP). As per the company's 2026 corporate presentation, a Phase IIb/III multiple-dose study is planned to initiate this year, with topline results anticipated in H1 2027.

Neuropathic Ocular Pain Companies
Novartis AG, SALVAT, AbbVie Inc., Bausch & Lomb Incorporated, Kala Pharmaceuticals, Spectra Vision Care., Alcon Laboratories, OKYO Pharma Limited, Ocular Therapeutix, Inc., IACTA Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., AERIE PHARMACEUTICALS, INC., Optocred Pharmaceuticals, BRIM Biotechnology, Inc, and others

Discover more about therapies set to grab major Neuropathic Ocular Pain market share @ https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Neuropathic Ocular Pain Market Outlook
The Neuropathic Ocular Pain (NOP) market is evolving from symptomatic care toward targeted therapies addressing corneal nerve dysfunction and inflammation. Existing treatments, including artificial tears, corticosteroids, serum tears, and systemic pain medications, often provide temporary relief. With no FDA-approved NOP-specific therapy, emerging products offer significant opportunities. OKYO Pharma's urcosimod (OK-101) has shown promising Phase II anti-inflammatory and pain-reducing results. The United States leads the market, while Europe and Japan demonstrate growing clinical interest.

Scope of the Neuropathic Ocular Pain Market Report
• Study Period: 2022-2036
• Historical Year: 2022-2025
• Base Year: 2026
• Forecast Period: 2026-2036
• Coverage: 7MM (United States; Germany, France, Italy, Spain, and the UK; Japan)
• Neuropathic Ocular Pain Companies: OKYO Pharma, and others
• Neuropathic Ocular Pain Therapies: Urcosimod (0.05%; OK-101), and others
• Neuropathic Ocular Pain Therapeutic Assessment: NOP current marketed and emerging therapies
• Neuropathic Ocular Pain Market Dynamics: NOP market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, Conjoint Analysis, Market entry strategies
• Neuropathic Ocular Pain Unmet Needs, KOL's views, Analyst's views, Neuropathic Ocular Pain Market Access and Reimbursement

To know more about Neuropathic Ocular Pain companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Neuropathic Ocular Pain (NOP)
4. Key Events
5. Epidemiology and Market Forecast Methodology
6. Neuropathic Ocular Pain (NOP) Market Overview at a Glance
7. Disease Background and Overview of Neuropathic Ocular Pain (NOP)
8. Treatment of Neuropathic Ocular Pain (NOP)
9. Epidemiology and Patient Population of Neuropathic Ocular Pain (NOP)
10. Patient Journey of Neuropathic Ocular Pain (NOP)
11. Emerging Drugs of Neuropathic Ocular Pain (NOP)
12. Neuropathic Ocular Pain (NOP): 7MM Analysis
13. Unmet Needs of Neuropathic Ocular Pain (NOP)
14. SWOT Analysis of Neuropathic Ocular Pain (NOP)
15. KOL Views of Neuropathic Ocular Pain (NOP)
16. Market Access and Reimbursement
17. KOL Views
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.